Mirae Asset Global Investments Co., Ltd. Cellectis S.A. Transaction History

Mirae Asset Global Investments Co., Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$2.29 - $4.08 $56,427 - $100,535	24,641 Added 13.25%	210,659 $482,000
Q2 2022 Jul 26, 2022	BUY	$2.39 - $4.93 $104,388 - $215,327	43,677 Added 30.68%	186,018 $526,000
Q1 2022 May 10, 2022	SELL	$3.45 - $8.77 $92,039 - $233,966	-26,678 Reduced 15.78%	142,341 $646,000
Q4 2021 Feb 08, 2022	BUY	$8.01 - $12.84 $366,553 - $587,584	45,762 Added 37.13%	169,019 $1.37 Million
Q3 2021 Nov 15, 2021	BUY	$11.94 - $16.09 $275,193 - $370,842	23,048 Added 23.0%	123,257 $1.55 Million
Q2 2021 Aug 11, 2021	BUY	$14.36 - $20.93 $79,152 - $115,366	5,512 Added 5.82%	100,209 $1.55 Million
Q1 2021 May 13, 2021	BUY	$18.19 - $33.25 $786,135 - $1.44 Million	43,218 Added 83.95%	94,697 $1.91 Million
Q4 2020 Feb 10, 2021	BUY	$15.87 - $31.64 $816,971 - $1.63 Million	51,479 New	51,479 $1.39 Million

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.